The treatment of type 2 diabetes in heart failure

Heart failure is a common complication associated with type 2 diabetes (T2DM) and the presence of both carries a poorer prognosis. Recent cardiovascular outcome trials have drawn attention to the contrasting effects of the different classes of agents used in the management of T2DM on heart failure outcomes. While SGLT-2 inhibitors and some GLP-1 agonists are associated with improved outcomes with regard to heart failure, thiazolidinediones and certain DPP-4 inhibitors have been shown to increase this risk. In this review article, we will review each of these drug classes and discuss the evidence, if any, for their use in heart failure. Copyright (c) 2018 John Wiley & Sons.